The pharma sector remains under a U.S. Section 232 investigation, with the outcome due by August.
Related Posts
Watch live: Robert F. Kennedy Jr. testifies at Senate confirmation hearing on his nomination to lead Health and Human Services
Robert F. Kennedy, Trump’s controversial pick to lead Health and Human Services, testifies before a Senate panel that is crucial to advance his nomination.
Target’s earnings whiff could put the spotlight on strained U.S. consumers
CEO Brian Cornell mentioned declining consumer confidence and uncertainty around tariffs as some of the issues facing the company during the latest quarter.
China cuts benchmark lending rates by 25 basis points
The move was not unexpected. China’s central bank governor indicated last week that the loan market benchmark rate would be lowered by 20 to 25 […]